These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Serelaxin a novel treatment for acute heart failure. Castrini AI; Carubelli V; Lazzarini V; Bonadei I; Lombardi C; Metra M Expert Rev Clin Pharmacol; 2015; 8(5):549-57. PubMed ID: 26294074 [TBL] [Abstract][Full Text] [Related]
4. Relaxin for the Treatment of Acute Decompensated Heart Failure: Pharmacology, Mechanisms of Action, and Clinical Evidence. Ng TM; Goland S; Elkayam U Cardiol Rev; 2016; 24(4):194-204. PubMed ID: 26331289 [TBL] [Abstract][Full Text] [Related]
5. Recent Progress in the Therapeutic Role of Serelaxin in Vascular Dysfunction. Murtaza G; Siddiqui A; Hussain I Curr Protein Pept Sci; 2018; 19(11):1079-1087. PubMed ID: 29984650 [TBL] [Abstract][Full Text] [Related]
6. The actions of relaxin on the human cardiovascular system. Sarwar M; Du XJ; Dschietzig TB; Summers RJ Br J Pharmacol; 2017 May; 174(10):933-949. PubMed ID: 27239943 [TBL] [Abstract][Full Text] [Related]
7. Recombinant human H2 relaxin (serelaxin) as a cardiovascular drug: aiming at the right target. Bani D Drug Discov Today; 2020 Jul; 25(7):1239-1244. PubMed ID: 32360533 [TBL] [Abstract][Full Text] [Related]
8. Serelaxin in acute heart failure: Most recent update on clinical and preclinical evidence. Ghosh RK; Banerjee K; Tummala R; Ball S; Ravakhah K; Gupta A Cardiovasc Ther; 2017 Feb; 35(1):55-63. PubMed ID: 27727514 [TBL] [Abstract][Full Text] [Related]
9. Emerging role of serelaxin in the therapeutic armamentarium for heart failure. Varr BC; Maurer MS Curr Atheroscler Rep; 2014 Oct; 16(10):447. PubMed ID: 25108571 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic effects of serelaxin in acute heart failure. Du XJ; Hewitson TD; Nguyen MN; Samuel CS Circ J; 2014; 78(3):542-52. PubMed ID: 24451687 [TBL] [Abstract][Full Text] [Related]
11. Effects of Serelaxin in Patients with Acute Heart Failure. Metra M; Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Pang PS; Ponikowski P; Voors AA; Adams KF; Anker SD; Arias-Mendoza A; Avendaño P; Bacal F; Böhm M; Bortman G; Cleland JGF; Cohen-Solal A; Crespo-Leiro MG; Dorobantu M; Echeverría LE; Ferrari R; Goland S; Goncalvesová E; Goudev A; Køber L; Lema-Osores J; Levy PD; McDonald K; Manga P; Merkely B; Mueller C; Pieske B; Silva-Cardoso J; Špinar J; Squire I; Stępińska J; Van Mieghem W; von Lewinski D; Wikström G; Yilmaz MB; Hagner N; Holbro T; Hua TA; Sabarwal SV; Severin T; Szecsödy P; Gimpelewicz C; N Engl J Med; 2019 Aug; 381(8):716-726. PubMed ID: 31433919 [TBL] [Abstract][Full Text] [Related]
12. Relaxin-2 as a Potential Biomarker in Cardiovascular Diseases. Aragón-Herrera A; Feijóo-Bandín S; Anido-Varela L; Moraña-Fernández S; Roselló-Lletí E; Portolés M; Tarazón E; Gualillo O; González-Juanatey JR; Lago F J Pers Med; 2022 Jun; 12(7):. PubMed ID: 35887517 [TBL] [Abstract][Full Text] [Related]
13. Serelaxin : a potential new drug for the treatment of acute heart failure. Neverova N; Teerlink JR Expert Opin Investig Drugs; 2014 Jul; 23(7):1017-26. PubMed ID: 24865798 [TBL] [Abstract][Full Text] [Related]
14. Serelaxin in clinical development: past, present and future. Unemori E Br J Pharmacol; 2017 May; 174(10):921-932. PubMed ID: 28009437 [TBL] [Abstract][Full Text] [Related]
15. Targeted biological therapies reach the heart: the case of serelaxin for heart failure. Kumar VA; Wilson SS; Ayaz SI; Levy PD Drugs Today (Barc); 2015 Oct; 51(10):591-7. PubMed ID: 26583301 [TBL] [Abstract][Full Text] [Related]
16. Serelaxin alleviates cardiac fibrosis through inhibiting endothelial-to-mesenchymal transition via RXFP1. Wilhelmi T; Xu X; Tan X; Hulshoff MS; Maamari S; Sossalla S; Zeisberg M; Zeisberg EM Theranostics; 2020; 10(9):3905-3924. PubMed ID: 32226528 [No Abstract] [Full Text] [Related]
17. 'Relaxin' the stiffened heart and arteries: the therapeutic potential for relaxin in the treatment of cardiovascular disease. Samuel CS; Du XJ; Bathgate RA; Summers RJ Pharmacol Ther; 2006 Nov; 112(2):529-52. PubMed ID: 16814863 [TBL] [Abstract][Full Text] [Related]
18. Development of a long-acting relaxin analogue, LY3540378, for treatment of chronic heart failure. Verdino P; Lee SL; Cooper FN; Cottle SR; Grealish PF; Hu CC; Meyer CM; Lin J; Copeland V; Porter G; Schroeder RL; Thompson TD; Porras LL; Dey A; Zhang HY; Beebe EC; Matkovich SJ; Coskun T; Balciunas AM; Ferrante A; Siegel R; Malherbe L; Bivi N; Paavola CD; Hansen RJ; Abernathy MM; Nwosu SO; Carr MC; Heuer JG; Wang X Br J Pharmacol; 2023 Aug; 180(15):1965-1980. PubMed ID: 36780899 [TBL] [Abstract][Full Text] [Related]
19. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Ponikowski P; Unemori E; Voors AA; Adams KF; Dorobantu MI; Grinfeld LR; Jondeau G; Marmor A; Masip J; Pang PS; Werdan K; Teichman SL; Trapani A; Bush CA; Saini R; Schumacher C; Severin TM; Metra M; Lancet; 2013 Jan; 381(9860):29-39. PubMed ID: 23141816 [TBL] [Abstract][Full Text] [Related]
20. Relaxin and the Cardiovascular System: from Basic Science to Clinical Practice. Martins RC; Pintalhão M; Leite-Moreira A; Castro-Chaves P Curr Mol Med; 2020; 20(3):167-184. PubMed ID: 31642776 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]